KoreaMed Synapse

Go to TopGo to Top Go to BottomGo to Bottom


1	크론병으로 인한 다발성 누공을 동반한 둔부와 천골전 농양 Hui Jeong Jwa, Hyun Joo Song, Hogyung Jun, Seong Taeg Kim, Sun-Jin Boo, Heung Up Kim, Donghyoun Lee Korean J Gastroenterol.2022;80(6):267-272. Published online 2022 December 25 DOI: http://dx.doi.org/10.4166/kjg.2022.088

2	Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies Haruka Otake, Satohiro Matsumoto, Hirosato Mashima Intest Res.2022;20(4):464-474. Published online 2022 March 31 DOI: http://dx.doi.org/10.5217/ir.2021.00139

3	Refractory brainstem encephalitis mimicking progressive cerebral infarction: infliximab and methotrexate as a salvage immunotherapy Sung-Ho Ahn, Jieun Roh, Kyoung-Nam Woo, Hyun-Sung Kim, Min-Gyu Park, Kyung-Pil Park, Seung-Kug Baik, Jin-Hong Shin J Neurocrit Care.2021;14(1):46-51. Published online 2021 March 10 DOI: http://dx.doi.org/10.18700/jnc.200025

4	Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang Yeungnam Univ J Med.2021;38(3):251-257. Published online 2021 February 19 DOI: http://dx.doi.org/10.12701/yujm.2020.00878

5	Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni, Sandeep Kaushal, Vineet Ahuja, Ajit Sood Intest Res.2022;20(1):64-71. Published online 2021 February 3 DOI: http://dx.doi.org/10.5217/ir.2020.00100

6	Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis Shin Ju Oh, Ga Young Shin, Hosim Soh, Jae Gon Lee, Jong Pil Im, Chang Soo Eun, Kang-Moon Lee, Dong Il Park, Dong Soo Han, Hyo Jong Kim, Chang Kyun Lee Intest Res.2021;19(3):323-331. Published online 2020 August 18 DOI: http://dx.doi.org/10.5217/ir.2020.00039

7	Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease? Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis Intest Res.2021;19(4):461-467. Published online 2020 August 18 DOI: http://dx.doi.org/10.5217/ir.2020.00042

8	Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab Hye-In Jung, Hyun Jung Kim, Ji-Min Kim, Ju Yup Lee, Kyung Sik Park, Kwang Bum Cho, Yoo Jin Lee Yeungnam Univ J Med.2020;38(1):70-73. Published online 2020 June 19 DOI: http://dx.doi.org/10.12701/yujm.2020.00304

9	Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies Hanna van Rheenen, Patrick Ferry van Rheenen Pediatr Gastroenterol Hepatol Nutr.2020;23(2):121-131. Published online 2020 March 4 DOI: http://dx.doi.org/10.5223/pghn.2020.23.2.121

10	Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians Soo-Kyung Park, Won Moon, Eun Soo Kim, Sang Hyun Park, Dong Il Park Korean J Gastroenterol.2019;74(6):333-340. Published online 2019 December 26 DOI: http://dx.doi.org/10.4166/kjg.2019.74.6.333

11	Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study Minkyung Han, Yoon Suk Jung, Jae Hee Cheon, Sohee Park Yonsei Med J.2020;61(1):48-55. Published online 2019 December 23 DOI: http://dx.doi.org/10.3349/ymj.2020.61.1.48

12	History and Future of Treatment for Acute Stage Kawasaki Disease Masahiro Ishii, Takasuke Ebato, Hirihisa Kato Korean Circ J.2020;50(2):112-119. Published online 2019 December 3 DOI: http://dx.doi.org/10.4070/kcj.2019.0290

13	The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis Suhwan Lee, Yu Jeong Park, Joo Yong Lee J Korean Med Sci.2019;34(42):e278. Published online 2019 October 18 DOI: http://dx.doi.org/10.3346/jkms.2019.34.e278

14	Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim Korean J Gastroenterol.2019;74(3):168-174. Published online 2019 September 27 DOI: http://dx.doi.org/10.4166/kjg.2019.74.3.168

15	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi Intest Res.2019;17(4):504-515. Published online 2019 August 23 DOI: http://dx.doi.org/10.5217/ir.2019.00030

16	Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease Min Hyung Woo, Young Hoon Cho, Min Ji Sohn, Eun Joo Lee, Ju Whi Kim, Jin Soo Moon, Jae Sung Ko, Hyun-young Kim Pediatr Gastroenterol Hepatol Nutr.2019;22(4):358-368. Published online 2019 June 25 DOI: http://dx.doi.org/10.5223/pghn.2019.22.4.358

17	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chian Lim, Wai Keung Leung, Raja Affendi Raja Ali, Deng Chyang Wu, Evan Ong, Nazri Mustaffa, Julajak Limsrivilai, Tadakazu Hisamatsu, Suk Kyun Yang, Qin Ouyang, Richard Geary, Janaka H De Silva, Rungsun Rerknimitr, Marcellus Simadibrata, Murdani Abdullah, Rupert WL Leong Intest Res.2019;17(3):285-310. Published online 2019 May 31 DOI: http://dx.doi.org/10.5217/ir.2019.00026

18	Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies Rintaro Moroi, Katsuya Endo, Katsutoshi Yamamoto, Takeo Naito, Motoyuki Onodera, Masatake Kuroha, Yoshitake Kanazawa, Tomoya Kimura, Yoichi Kakuta, Atsushi Masamune, Yoshitaka Kinouchi, Tooru Shimosegawa Intest Res.2019;17(1):94-106. Published online 2018 December 3 DOI: http://dx.doi.org/10.5217/ir.2018.00048

19	Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea Gyu Hur, Min Seob Song, Sejung Sohn, Hyoung Doo Lee, Gi Beom Kim, Hwa Jin Cho, Kyung Lim Yoon, Chan Uhng Joo, Myung Chul Hyun, Chul Ho Kim Korean Circ J.2019;49(2):183-191. Published online 2018 November 8 DOI: http://dx.doi.org/10.4070/kcj.2018.0214

20	Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study Akihiro Koga, Toshiyuki Matsui, Noritaka Takatsu, Yasumichi Takada, Masahiro Kishi, Yutaka Yano, Takahiro Beppu, Yoichiro Ono, Kazeo Ninomiya, Fumihito Hirai, Takashi Nagahama, Takashi Hisabe, Yasuhiro Takaki, Kenshi Yao, Hirotsugu Imaeda, Akira Andoh Intest Res.2018;16(2):223-232. Published online 2018 April 30 DOI: http://dx.doi.org/10.5217/ir.2018.16.2.223